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Dimethylfumarate Specifically Inhibits the Mitogen
and Stress-Activated Kinases 1 and 2 (MSK1/2):
Possible Role for its Anti-Psoriatic Effect
Borbala Gesser1, Claus Johansen1, Mads K. Rasmussen1, Anne T. Funding1, Kristian Otkjaer1,
Rasmus B. Kjellerup1, Knud Kragballe1 and Lars Iversen1
The p38 mitogen-activated protein kinase (MAPK) signaling pathway, which regulates the activity of different
transcriptions factors including NF-kB, is activated in lesional psoriatic skin. The purpose of this study was to
investigate the effect of fumaric acid esters (FAEs) on the p38 MAPK and the downstream kinases mitogen- and
stress-activated protein kinase (MSK)1 and 2 in cultured human keratinocytes. Cell cultures were incubated with
dimethylfumarate (DMF), methylhydrogenfumarate (MHF), or fumaric acid (FA) and then stimulated with IL-1b
before kinase activation was determined by Western blotting. A significant inhibition of both MSK1 and 2
activations was seen after preincubation with DMF and stimulation with IL-1b, whereas MHF and FA had no
effect. In addition, DMF decreased phosphorylation of NF-kB/p65 (Ser276), which is known to be transactivated
by MSK1. Furthermore, incubation with DMF before stimulation with IL-1b resulted in a significant decrease in
NF-kB binding to the IL-8 kB and the IL-20 kB-binding sites as well as a subsequent decrease in IL-8 and IL-20
mRNA expression. Our results suggest that DMF specifically inhibits MSK1 and 2 activations and subsequently
inhibits NF-kB-induced gene–transcriptions, which are believed to be important in the pathogenesis of
psoriasis. These effects of DMF explain the anti-psoriatic effect of FAEs.
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INTRODUCTION
Various combinations of fumaric acid esters (FAEs) have been
used empirically for oral treatment of psoriasis for more than
40 years (Mrowietz and Asadullah, 2005). In 1989, the
efficacy of dimethylfumarate (DMF) in psoriasis was demon-
strated for the first time in a controlled study (Nieboer et al.,
1989) and in 1994 a mixture of different FAEs (including DMF
and methylhydrogenfumarate (MHF)) was registered in
Germany as Fumaderms initial (low-strength tablets) and
Fumaderms (high-strength tablets) for systemic treatment of
severe psoriasis. DMF and, in part, MHF or their metabolites
are considered to be the main active ingredients of
Fumaderms. Fumaderms has become the number one drug
for systemic therapy in Germany (Mrowietz and Asadullah,
2005) although its precise mechanism of action is still
unknown.
A number of studies have tried to elucidate the mode of
action of FAEs in psoriasis. FAEs have been shown to induce a
shift of the immunological balance from a T helper 1- towards
a T helper 2-like response (De Jong et al., 1996), and
especially DMF has been shown to inhibit the transcription
and protein expression of different inflammatory mediators
including IL-8, Mig, and IP-10 in peripheral blood mono-
nuclear cells (Ockenfels et al., 1998) and in normal human
keratinocytes (Stoof et al., 2001). In human umbilical vein
endothelial cells, DMF has also been shown to modulate
adhesion molecule expression by blocking tumor necrosis
factor (TNF)a-induced expression of ICAM-1, vascular cell
adhesion molecule-1, and E-selectin (Vandermeeren et al.,
1997). Furthermore, DMF has been shown to induce
apoptosis in U937-cells (Sebok et al., 2000), and in purified
human T cells (Treumer et al., 2003).
The cellular redox system is also modulated by FAEs. In
animal experiments, where DMF was added to the diet, a
significant modulation of intracellular levels of detoxifying
enzyme systems like the reduced glutathione (GSH) –
oxidized glutathione–disulfide (GSSG) system were seen
(Spencer et al., 1990). In particular, an upregulation of the
GSH level was seen after dietary supplementation.
NF-kB is a dimeric nuclear transcription factor also
regulated by FAEs in vitro. Interestingly, a dysregulation of
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NF-kB activation in lesional psoriatic skin compared with
nonlesional psoriatic skin has been demonstrated (Johansen
et al., 2005a). Furthermore, downregulation of NF-kB
transcriptional activity has been suggested as a possible
mode of action of anti-TNFa therapy for psoriasis (Lizzul
et al., 2005).
NF-kB is a dimer formed by members of the NF-kB/Rel
family of proteins, consisting of p50, p52, p65, c-Rel, and
RelB (Liou and Baltimore, 1993; Baeuerle and Henkel, 1994).
In resting cells, NF-kB is retained in the cytoplasm as an
inactive complex with inhibitor kB, which masks the nuclear
localization sequences of NF-kB (Baldwin, 1996). Thus,
cellular stimulation results in phosphorylation, ubiquitina-
tion, and subsequent degradation of inhibitor kB, unmasking
the nuclear localization sequences, and leaving NF-kB free to
translocate into the nucleus where it binds to specific
kB-binding sites in its target genes (Pahl, 1999).
Recently, DMF has been shown to prevent selectively the
nuclear entry of activated NF-kB in TNFa-stimulated human
endothelial cells (Loewe et al., 2002). In human dendritic
cells, both DMF and MHF have an inhibitory effect on
lipopolysaccharide-induced NF-kB activation (Litjens et al.,
2004).
NF-kB is believed to play a pivotal role in immune and
inflammatory responses by stimulating the expression of a
number of adhesion molecules as well as proinflammatory
cytokines and chemokines (Karin and Ben-Neriah, 2000).
NF-kB activation also results in a protective effect against
apoptotic cell death (Sonenshein, 1997). Furthermore, an
increased GSH level inhibits NF-kB activation (Perl et al.,
2002). In view of these observations, inhibition of NF-kB has
recently been suggested as the molecular target of DMF and
MHF in psoriasis (Mrowietz and Asadullah, 2005).
Recently, increased kinase activity of the p38 mitogen-
activated protein kinase (MAPK) cascade has also been
demonstrated in lesional psoriatic skin compared with
nonlesional psoriatic skin (Johansen et al., 2005b), and has
been suggested to play an important role in the pathogenesis
of psoriasis (Arthur and Darragh, 2006). The p38 MAPK
cascade is able to activate additional downstream kinases
and at least two of these downstream kinases, MAPK-
activated protein kinase 2 (MK2) and mitogen- and stress-
activated protein kinase 1 (MSK1), are activated in lesional
psoriatic skin (Johansen et al., 2006; Funding et al., 2006).
MK2 is thought to control cytokine production at a
posttranscriptional level, whereas MSK1 and the related
kinase MSK2 regulate gene transcription through transactiva-
tion of different transcription factors. MSK1 has been shown
to phosphorylate various transcription factors including
cAMP-response element-binding protein (CREB) (Deak
et al., 1998), the CREB-related protein, ATF-1 (Wiggin
et al., 2002), and the p65 subunit of NF-kB at Ser276
(Vermeulen et al., 2003) leading to increased transcriptional
activity.
The purpose of this study was, therefore, to investigate the
effect of FAEs on the p38 MAPK signaling pathway including
some of its downstream kinases in cultured normal human
keratinocytes. In this paper, we demonstrate for the first time
that DMF, but not MHF, specifically inhibits MSK1 and 2
activation and NF-kB/p65 transactivation through inhibition
of Ser276 phosphorylation, whereas no changes in p38
MAPK and MK2 activation were seen. DMF may, therefore,
inhibit both NF-kB nuclear translocation and NF-kB transac-
tivation and thereby exert its anti-psoriatic effect.
RESULTS
Effect of DMF, MHF, and FA on IL-1b-induced p38 MAPK, ERK
p44/p42, and MK2 activation in normal human keratinocytes
in vitro
To investigate the protein level of activated p38 MAPK,
whole-cell extracts from IL-1b-stimulated cultured normal
human keratinocytes were isolated and analyzed by Western
blotting using an anti-phospho-p38 MAPK (Thr180/Tyr182)
antibody. IL-1b (20 ng/ml) stimulation resulted in a pro-
nounced activation of the p38 MAPK at 5, 15, and 30 minutes
after stimulation compared with vehicle. Thus, no significant
changes in p38 MAPK activation were seen after preincuba-
tion with DMF (140 mM), MHF (140 mM), or FA (140 mM) for
1 hour and no changes were seen in the expression of total
p38 MAPK (Figure 1a). These findings were confirmed by
densitometric analysis of band intensity of the Western blots
(data not shown).
The extracellular signal-regulated kinase (ERK) p44/p42 is
another MAPK which regulate cell proliferation. ERK p44/p42
activation in whole-cell extracts from cultured normal human
keratinocytes preincubated with vehicle, DMF (140 mM), MHF
(140 mM), or FA (140mM) for 1 hour before stimulation with IL-
1b (20 ng/ml) for various time points were analyzed by
Western blotting using an anti-phospho-ERK p44/p42
(Thr202/Tyr204) antibody. After stimulation for 5 minutes, a
significant activation of both ERK p44 and p42 was seen
(Figure 1b). However, no changes in ERK p44/p42 activation
were seen after preincubation with DMF, MHF, and FA.
Equal protein loading was confirmed by detection of total
ERK p44/p42 (Figure 1b).
MK2 is a serine/threonine kinase that is activated by the
p38 MAPK through phosphorylation at threonine 334 (Roux
and Blenis, 2004). In experiments conducted as described
above, stimulation with IL-1b (20 ng/ml) of cultured normal
human keratinocytes resulted in MK2 activation after 5 and
15 minutes determined by Western blotting using an anti-
phospho-MK2 (Thr334) antibody. Again, preincubation with
DMF (140mM), MHF (140mM), or FA (140 mM) before IL-1b
stimulation did not result in any significant changes in MK2
activation (Figure 1c). Equal protein loading was confirmed
by detection of total MK2.
Effect of DMF, MHF, and FA on IL-1b-induced MSK1 and 2
activations in normal human keratinocytes in vitro
MSK1 and 2 are activated by both p38 MAPKs and ERK p44/
42. In keratinocytes, however, the IL-1b-induced MSK1
activation is only dependent on the p38 MAPK signaling
pathway (Funding et al., 2006). MSK1 is activated by
phosphorylation at Ser376 and Thr581 (McCoy et al.,
2005). Equivalent amounts of whole cell protein extracts
from cultured normal human keratinocytes preincubated with
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either vehicle, DMF (140mM), MHF (140 mM), or FA (140 mM)
and then stimulated with IL-1b (20 ng/ml) for various time
points were analyzed by Western blotting using anti-
phospho-MSK1 (Ser376). Stimulation with IL-1b resulted in
a significant activation of MSK1 after stimulation for 15 and
30 minutes (Figure 2a). Thus, preincubation with DMF
consistently and significantly inhibited MSK1 activation,
whereas MHF or FA did not result in any significant changes
in MSK1 activation (Figure 2a).
MSK1 and MSK2 are closely related nuclear kinases, and
results indicate that MSK1 and 2 may be able to compensate
functionally for each other (Wiggin et al., 2002). In IL-1b-
stimulated keratinocytes, MSK2 was also activated at
15–30 minutes after stimulation. Preincubation with DMF
before IL-1b stimulation significantly abolished MSK2 phos-
phorylation at Ser196, whereas MHF and FA had no effect
(Figure 2b).
In dose-finding experiments, keratinocyte cultures were
preincubated with 7, 70, or 140 mM DMF before stimulated
with IL-1b 20 ng/ml for 15 and 30 minutes. There was a dose-
dependent inhibition of MSK1 (Ser376) phosphorylation with
a maximal inhibition at 140 mM DMF (Figure 2c).
Furthermore, cell viability was tested by lactate dehydro-
genase (LDH) release in cells incubated with or without 140,
70, or 7 mM DMF for 1 hour and stimulated with IL-1b for
30 minutes. No significant difference was found between
control cells and cells incubated with DMF (Table 1).
Effect of DMF, MHF, and FA on IL-1b-induced phosphorylation
of CREB and the CREB-related protein, ATF-1
CREB and activation transcription factor 1 (ATF1) are both
transcription factors activated through the MSK1 and 2
signaling pathway (Deak et al., 1998; Wiggin et al., 2002).
To study the effect of FAEs on MSK1 and 2 downstream
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Figure 1. Effect of DMF, MHF, and FA on IL-1b-induced phosphorylation of
(a) p38, (b) ERK1/2, and (c) MK2. Cultured normal human keratinocytes
were preincubated with 140mM of DMF, MHF, or FA for 1 hour and then
stimulated with 20 ng/ml of IL-1b for 5, 15, 30 minutes or 2 hours. Whole-cell
extracts (50 mg of protein) were isolated and separated by SDS–PAGE on
10–20% gradient gels. After electroblotting, the separated proteins were
probed with (a) anti-phospho p38, (b) anti-phospho-ERK1/2, (c) or anti-
phospho-MK2. Blots were then stripped and equal loading was confirmed by
incubation with anti-p38, anti-ERK1/2, or anti-MK2 antibodies. As a positive
control (pc) for phospho-MK2 keratinocytes were stimulated for 5 minutes
with anisomycin (0.5 mg/ml). One representative Western blot out of four is
shown.
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Figure 2. Effect of DMF, MHF, and FA on IL-1b-induced phosphorylation of
(a) MSK1 and (b) MSK2. Cultured normal human keratinocytes were
preincubated with 140 mM of DMF, MHF, or FA for 1 hour and then stimulated
with 20 ng/ml of IL-1b for 5, 15, 30 minutes or 2 hours. (c) In separate
experiments cells were preincubated with different concentrations of DMF (7,
70, or 140 mM) before stimulation with IL-1b (20 ng/ml) for 15 and 30 minutes.
Whole cell-extracts (50 mg of protein) were isolated and separated by
SDS–PAGE on 10–20 % gradient gels. After electroblotting, the separated
proteins were probed with (a and c) anti-phospho-MSK1 (Ser376) or (b) anti-
phospho-MSK2 (Ser196). Blots were then stripped and equal loading was
confirmed by reincubation with anti-MSK1 and -MSK2 antibodies. As a
positive control (pc) keratinocytes were stimulated for 15 minutes with
anisomycin (0.5 mg/ml). One representative Western blot out of five is shown.
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targets, cultured normal human keratinocytes were preincu-
bated with either DMF (140mM), MHF (140 mM), or FA
(140 mM) 1 hour before stimulated with IL-1b (20 ng/ml) for
various time points.
Western blotting of equivalent amounts of whole-cell
extracts was performed and analyzed for phospho-CREB
(Ser133) and total CREB expression. Equal protein loading
was confirmed by detection of total b-actin. IL-1b stimulation
resulted in a consistent and significant increase in CREB
phosphorylation at 5, 15, and 30 minutes (Figure 3a).
Preincubation with DMF strongly and significantly inhibited
CREB phosphorylation at Ser133 (Figure 3a). Densitometric
analysis of band intensity confirmed the significant decrease
at all time points in phospho-CREB expression in keratino-
cytes preincubated with DMF and stimulated with IL-1b
compared with controls (Figure 3c). Preincubation with DMF
also lead to consistent and, after 15 minutes of stimulation
with IL-1b, also significant decrease in total CREB expression
compared with controls (Figure 3a and d). When expressing
phospho-CREB relative to total CREB, a significant decrease
in phospho-CREB expression was seen only before IL-1b
stimulation and after 5 minutes of stimulation (Figure 3b). No
effect of preincubation with neither MHF nor FA was seen
(Figure 3a).
The anti-phospho-CREB antibody also detects the phos-
phorylated form of the CREB-related protein, ATF-1, and
similarly to CREB, pre-incubation with DMF resulted in a
significant inhibition in the IL-1b-induced phosphorylation of
ATF-1, whereas no effects were seen on preincubation with
MHF or FA (Figure 3). Equal protein loading was demon-
strated by detection of b-actin.
DMF inhibits IL-1b-induced phosphorylation of p65 (Ser276)
in normal keratinocytes in vitro
To examine further the downstream targets of MSK-1, NF-kB
transactivation was investigated by determining p65 phos-
phorylation at Ser276 in cultured normal human keratino-
cytes after preincubation with DMF (140 mM) MHF (140mM),
or FA (140mM) and stimulation with IL-1b (20 ng/ml) for either
15 or 30 minutes.
P65 phosphorylation at Ser276 was analyzed by Western
blotting of either nuclear (Figure 4a) or cytosolic (Figure 4b)
protein extracts using a specific anti-p65-phospho-Ser276 or
an anti-p65 antibody. Stimulation with IL-1b resulted in a
Table 1. Cytotoxicity in percent of maximum LDH
release control
DMF 140 lM DMF 70 lM DMF 7 lM
Control 20.4770.034 19.4970.31 17.3270.02
IL-1b 21.8670.11 23.2870.05 18.7970.30
DMF+IL-1b 21.5670.47 20.3170.01 18.5070.12
DMF 18.8370.62 19.4170.03 17.9570.58
DMF, dimethylfumarate.
Cultured normal human keratinocytes were either preincubated with
vehicle or 7, 70, or 140 mM of DMF for 1 hour before stimulated with
vehicle or 20 ng/ml of IL-1b for 30 minutes.
Maximum LDH release control was 2 ml of lysis solution added to control
cells.
Percent cytotoxicity was calculated as ratio 100 experimental/maximum
LDH release.
Results represent mean7SD from three experiments assayed in dupli-
cates.
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Figure 3. Effect of DMF, MHF and FA on IL-1b-induced phosphorylation of
CREB. Cultured normal human keratinocytes were preincubated with 140 mM
of DMF, MHF, or FA for 1 hour and then stimulated with 20 ng/ml of IL-1b for
5, 15, 30 minutes or 2 hours. Whole-cell extracts (50 mg/ml of protein) were
isolated and separated by SDS–PAGE on 10–20% gradient gels. After electro
blotting, the separated proteins were probed with anti-phospho-CREB. Blots
were then stripped and probed with an anti-CREB antibody. Then the blots
were stripped again and reincubated with a b-actin antibody as a control for
equal loading. (a) One representative Western blot out of four is shown.
Quantitation by densitometric analysis of band intensity of p-CREB relative to
total (b) CREB and (c) p-CREB as well as (d) total CREB are shown. Result
represents mean7SD from four experiments (*Po0.05).
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significant (Po0.05) increased phosphorylation of p65-
Ser276 in both the nuclear (Figure 4a) and the cytosolic
(Figure 4b) fraction after stimulation for 15 and 30 minutes.
Furthermore, a significant increase in total p65 was seen in
the nuclear fraction after IL-1b stimulation (Figure 4a).
Preincubation with DMF strongly inhibited p65 phosphory-
lation at Ser276 in both the nuclear (Figure 4a) and the
cytosolic (Figure 4b) fraction. Furthermore, DMF clearly
inhibited p65 translocation into the nucleus (Figure 4a).
Preincubation with neither FA nor MHF resulted in any
significant changes in p65 phosphorylation or NF-kB nuclear
translocation.
To asses the purity of the nuclear and the cytosolic
fraction, lamin B was used as marker for nuclear protein
(Brasier et al., 2001). Using an anti-lamin B antibody, there
was reactivity in the nuclear fraction but not in the cytosolic
fraction (Figure 4).
DMF inhibits IL-1b-induced NF-jB binding to the IL-8 jB-
and the IL-20 jB-binding sites in normal human keratinocytes
in vitro
Nuclear fractions were isolated from keratinocytes preincu-
bated with either vehicle, DMF (140 mM), MHF (140 mM), or
FA (140 mM) before being stimulated with IL-1b (20 ng/ml) or
vehicle for 0 or 30 minutes. Nuclear fractions from cultured
keratinocytes were incubated with an oligonucleotide con-
taining the kB-binding site from the IL-8-promotor region or
an oligonucleotide containing one of the two recently
identified kB-binding sites in the IL-20 promoter (see
Materials and Methods) and analyzed by electrophoretic
mobility shift assay. Supershift analyzes of the NF-kB-binding
complexes were also carried out using antibodies directed
against the p65 or the p50 proteins.
IL-1b stimulation for 30 minutes significantly induced NF-
kB binding to the IL-8 motif as well as the two IL-20 kB motifs
(Figure 5). Preincubation with DMF significantly inhibited
NF-kB binding to the IL-8 kB-binding motif (Figure 5a) as well
as to one of the two identified IL-20 kB (B1)-binding motifs
(Figure 5b and c). Preincubation with MHF or FA did not
result in any changes in the NF-kB binding to the tested kB-
binding sites. Supershift experiments showed that addition of
an anti-p65 antibody resulted in a complete shift of both the
IL-8 kB complex as well as the two IL-20 kB complexes,
whereas addition of an anti-p50 antibody only partly shifted
the binding to the IL-8 kB complex (Figure 5a–c).
DMF inhibits IL-1b-induced IL-8 and IL-20 mRNA expression
IL-1b-induced IL-8 and IL-20 mRNA expression in cultured
human keratinocytes is dependent on NF-kB activation
(Johansen et al., 2005a; Otkjaer et al., 2005, 2007). Because
DMF inhibits NF-kB binding to the IL-8- and IL-20 kB-
binding sites and also inhibits NF-kB transactivation, experi-
ment were conducted to determine the effect of DMF on IL-
1b-induced IL-8 and IL-20 mRNA expression in cultured
normal human keratinocytes. Keratinocytes were preincu-
bated with or without DMF (140 mM) for 1 hour before
stimulation with IL-1b (20 ng/ml). IL-8 and IL-20 mRNA
expression at 12 and 1 hour respectively were analyzed by
quantitative reverse transcription–PCR and showed a con-
sistent and significant inhibition of both IL-8 and IL-20 mRNA
expression in cells preincubated with DMF (n¼4) (Figure 6).
IL-20 mRNA expression was inhibited to approximately basal
level (Figure 6).
DISCUSSION
In this study, we have presented three interesting and novel
observations all of which provide new important information
regarding the mechanism of action of DMF in psoriasis. First,
DMF specifically inhibits IL-1b-induced MSK1 and 2 activa-
tions in normal cultured human keratinocytes, whereas other
kinases within the p38 MAPK signaling pathway were not
affected. Second, DMF was shown to inhibit transactivation
of transcription factors such as NF-kB, CREB, and ATF1,
which are all downstream targets of the MSK1 and 2 signaling
pathway; and finally, DMF has been shown to inhibit IL-1b-
induced expression of IL-8 and IL-20 mRNA, both genes
activated by NF-kB.
MSK1 is expressed in epidermal keratinocytes and has
been shown to be highly activated in lesional psoriatic skin
(Funding et al., 2006). It has been suggested to play a key role
in the pathogenesis of psoriasis (Arthur and Darragh, 2006;
Funding et al., 2006). MSK1 is activated by the p38 MAPK or
the ERK p44/42 MAPKs through phosphorylation of either
Ser376 or Thr581 and phosphorylation of Ser376 is required
for MSK1 activation (Chrestensen and Sturgill, 2002). MSK2 is
not as well characterized as MSK1 although MSK2 is 75%
identical to MSK1 (Vermeulen et al., 2002). MSK2 is
activated through phosphorylation of Ser196 (Roux and
Blenis, 2004), and evidence from knockout mice has
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Figure 4. Effect of DMF, MHF, and FA on IL-1b-induced phosphorylation of
NF-jB p65. Cultured normal human keratinocytes were preincubated with
140mM of DMF, MHF, or FA for 1 hour and then stimulated with 20 ng/ml of
IL-1b for 15 and 30 minutes. (a) Nuclear (10mg) and (b) cytosolic (50 mg)
protein extracts were prepared and separated by SDS–PAGE on 8–16% radient
gels. After electroblotting, the separated proteins were probed with
anti-phospho-p65 (Ser276). Blots were then stripped and probed with
anti-p65 antibody. Equal loading was confirmed by reincubation with
b-actin antibody. The same fractions were probed with anti-lamin B antibody.
Lamin B is a marker for nuclear protein. One representative Western blot out
of three is shown.
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suggested an overlapping effect of MSK1 and MSK2. It is,
therefore, interesting that DMF inhibits IL-1b-induced activa-
tion of both MSK1 and 2. Inhibition of MSK1 and 2
activations was not seen when cells were preincubated with
MHF or FA strongly supporting that DMF or one of its
metabolites is the active compound in the mixture of FAEs
used in psoriasis (Nieboer et al., 1989). Furthermore, the
inhibitory effect of DMF on MSK 1 and 2 was specific,
because other kinases such as p38 MAPK, ERK p44/p42
MAPK, and MK2 were not affected. The DMF concentration
causing maximal inhibition of MSK1 and MSK2 activation in
keratinocytes was similar to that found in T cells (Treumer
et al., 2003).
Activation of NF-kB by proinflammatory stimuli leads to
the expression of genes inducing and maintaining inflamma-
tion and NF-kB has been shown to be activated at sites of
inflammation in a variety of diseases including psoriasis (Tak
and Firestein, 2001; Johansen et al., 2005a, b; Lizzul et al.,
2005). Therefore, NF-kB is considered a potential target for
treating inflammatory diseases.
In previous studies in endothelial cells, DMF was shown to
inhibit TNF-induced gene expression through a mechanism
involving NF-kB inhibition (Loewe et al., 2001; Vandermee-
ren et al., 2001). The NF-kB inhibition was mediated through
an inhibition of TNFa-induced nuclear entry of p65, whereas
there was no inhibition of the TNFa-induced signaling to IkB
(Loewe et al., 2001, 2002). Therefore, DMF was concluded to
inhibit NF-kB activation by interfering with translocation of
NF-kB to the nucleus. A similar mechanism of action was
demonstrated in normal human keratinocytes in this study
(Figure 4). Besides interfering with NF-kB nuclear entry, DMF
inhibited NF-kB transactivation through inhibition of MSK1
and 2 activities. This has never been demonstrated before.
MSK1 has previously been shown to phosphorylate NF-kB/
p65 at Ser276 in mouse fibroblasts (Vermeulen et al., 2002,
2003) and similar results were obtained in this study in
cultured normal human keratinocytes. Interestingly, phos-
phorylation of NF-kB/p65 at Ser276 has been shown to be
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Figure 5. Effect of DMF, MHF, and FA on NF-jB DNA binding. Cultured
human keratinocytes were pr-incubated with 140 mM of DMF, MHF, or FA for
1 hour and then stimulated with 20 ng/ml of IL-1b for 30 minutes. Nuclear
proteins were prepared and 5 mg of protein was incubated with a labeled
oligonucleotide identical to either the kB site from the (a) IL-8 promoter or
(b) the IL-20 promoter site B, and (c) B1. The NF-kB-binding activity was then
determined by electrophoretic mobility shift assay. Supershift analysis of the
NF-kB dimers was carried out. Antibodies for p65 and p50 were added
10 minutes before the labeled oligonucleotides. One representative Western
blot out of three is shown.
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Figure 6. Effect of DMF on IL-8 and IL-20 mRNA expression. Cultured
normal human keratinocytes were preincubated with vehicle or 140 mM of
DMF for 1 hour and then stimulated with vehicle or 20 ng/ml of IL-1b for 12
and 1 hours. Optimal induction of IL-8 and IL-20 mRNA was obtained after 12
and 1 hours of incubation, respectively. Expression of IL-8 and IL-20 mRNA
levels were analyzed by quantitative reverse transcriptase–PCR. The amount
of mRNA was determined relative to the house-keeping gene 18S rRNA.
Results represent mean7SD from four different experiments.
All measurements were performed in doublets (*Po0.05).
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essential for transcriptional activation by MSK1 (Vermeulen
et al., 2003). Inhibition of Ser276 phosphorylation of NF-kB/
p65 by DMF is therefore a novel mechanism of action by
which DMF inhibits NF-kB activation.
MSK1 is regarded a nuclear kinase for NF-kB/p65
(Vermeulen et al., 2003) and this explains why DMF was
able to inhibit phosphorylation of the nuclear p65 at Ser276.
Recently, MSK1 was also identified in the cytoplasm (Funding
et al., 2006), which may explain why DMF inhibited NF-kB/
p65 phosphorylation at Ser276 in the cytosolic fraction
(Figure 4). The localization of MSK2 has not yet been
investigated in the skin.
MSK1 and 2 phosphorylate various other transcription
factors including CREB and ATF1 (Deak et al., 1998; Pierrat
et al., 1998; Wiggin et al., 2002). Our results showed
increased phosphorylation of both CREB and ATF1 after
stimulation of normal cultured human keratinocytes with IL-
1b. Furthermore, preincubation with DMF in IL-1b-stimulated
cultures inhibited both CREB and ATF1 phosphorylation
(Figure 3), most probably through an inhibition of MSK1 and
2 activations. Thus, we also observed lower levels of total
CREB in the DMF-treated cells. These results are in agreement
with Mouravlev et al. (2006), which showed that phosphor-
ylation at Ser133 prevented CREB degradation in human
embryonic kidney cells. Similarly, the stability of ATF2,
which shares 65% homology with CREB, was shown to be
regulated by phosphorylation and dephosphorylation (Fuchs
et al., 2000). Therefore, the lower levels of total CREB in the
DMFþ IL-1b-treated cells compared with IL-1b alone (Fig-
ure 3) can be explained by the fact that DMF inhibits MSK1-
and 2-induced CREB phosphorylation and thereby indirectly
stimulates CREB degradation. Interestingly, a very recently
published study (Schiller et al., 2006) showed that MSK1 is
critical for IL-1-induced CREB-mediated, c-fos gene expres-
sion in the human keratinocyte cell line HaCaT. Our results,
therefore, suggest that specific inhibition of MSK1 and 2 is a
key mode of action by which DMF inhibits transactivation of
different transcriptions factors regulating the expression of
proinflammatory genes.
DMF has previously been shown to inhibit IL-8 expression
in lipopolysaccharide-stimulated peripheral blood mono-
nuclear cells (Ockenfels et al., 1998). In cultured normal
human keratinocytes, pretreatment with DMF before stimula-
tion with phorbol–ester or INFg resulted in an inhibition of
both IL-8 mRNA and protein expression (Stoof et al., 2001).
These results are in agreement with results obtained in this
study. Thus, we found an inhibition of NF-kB binding to a
possible IL-20 kB1-binding site as well as a pronounced
inhibition of IL-20 mRNA expression after preincubation with
DMF and stimulation with IL-1b (Figures 5 and 6). IL-20
mRNA expression was inhibited to a level comparable with
unstimulated cells. IL-20 is a recently discovered cytokine
belonging to the IL-10 family of cytokines (Blumberg et al.,
2001). It is expressed in the skin and IL-20 mRNA has been
shown to be upregulated in lesional psoriatic skin compared
with nonlesional psoriatic skin (Romer et al., 2003; Otkjaer
et al., 2005). Furthermore, IL-20 mRNA expression decreases
in parallel with clinical and histological improvement of the
skin during treatment (Otkjaer et al., 2005). Therefore, IL-20
has been suggested as a key cytokine in the pathogenesis of
psoriasis (Blumberg et al., 2001; Otkjaer et al., 2005) and
inhibition of IL-20 expression may also be an important part
of the anti-psoriatic effect of DMF.
New results (Otkjaer et al., 2007) have shown that IL-1b-
induced IL-20 mRNA and protein expression is regulated
through p38 MAPK- and NF-kB-dependent pathways. The
pronounced inhibitory effect of DMF on IL-20 expression is
therefore, most probably owing to its inhibitory effect on both
NF-kB translocation and p38 MAPK/MSK1- and 2-mediated
transactivation of NF-kB.
Taken together, the results presented in this study add new
information regarding the mode of action of DMF in the
treatment of psoriasis. Our findings identify DMF as the
pharmacologically active compound when compared with
MHF and FA regarding inhibition of NF-kB nuclear translo-
cation and inhibition of NF-kB transactivation are suggested
as key mechanisms of action of DMF.
MATERIALS AND METHODS
Cell cultures
Normal adult human keratinocytes were obtained by trypsinization
of skin samples from patients undergoing plastic surgery as described
previously (Kragballe et al., 1985). First passage keratinocytes were
grown in keratinocyte serum-free medium (Invitrogen, Carlsbad,
CA). Twenty-four hours before IL-1b stimulation (20 ng/ml; R&D
Systems, Oxon, UK), the medium was changed to keratinocyte basal
medium (the same as keratinocyte serum-free medium but without
growth factors) in which the cells were stimulated. Cells were grown
at 371C and 5% CO2 in an incubator.
The study was conducted according to the institutional approval
of experiments, patient consent and adherence to the Declaration of
Helsinki Principles.
DMF and calcium methyl hydrogen fumarate (Fumapharm, Luzern,
Switzerland) and FA (F8509, Sigma Aldrich) were solubilized in
DMSO (Art. 2951, Merck) and diluted to 70 mM stock solutions (2% v/v
DMSO) in keratinocyte basal medium. Treatment of cells with DMF,
MHF, and FA were further diluted in medium for final concentrations
7, 70, and 140mM. All stock solutions were freshly made 10 minutes
before use. Cells were preincubated with DMF, MHF, or FA 1 hour
before stimulation with IL-1b (R&D Systems).
Western blotting
Cells were washed two times with ice-cold PBS buffer and kept at
801C until further treatment. Whole-cell extracts were prepared in
sample buffer (50 mM Tris–HCl, 10% glycerol, 2.5% SDS, 10 mM
dithioerythritol, 10 mM b-glycerophosphate, 10 mM NaF, 100 mM Na
orthovanadate, 7 M urea; U-6504, Sigma) with 1 ml benzonase
(Merck 1.01654.001)/100 ml sample buffer. Equal load of protein
(determined by Bradford) was separated on precast SDS–PAGE, 8–16
or 10–20% Tris–glycine gels. (Invitrogen, Denmark; EC60452 box or
EC61352 box). Generally, 50 mg of protein was applied to gels. Equal
load was controlled by antibody for b-actin (A-1978, Sigma).
Alternatively, nuclear lysates were prepared according to Johansen
et al. (2000, 2005a). The purity of the nuclear and cytosolic lysates
was controlled by antibody for lamin B (Santa Cruz Biotechnology,
Santa Cruz, CA). Proteins were blotted onto hybond enhanced
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chemoluminescence nitrocellulose membrane (RPN2020D; Amer-
sham Bioscience, GE Healthcare, Denmark) blocked and developed
according to the instructions from Cell Signaling Technology
(Beverly, MA) for the specific antibody. The antibody binding was
visualized by horseradish peroxidase-conjugated second antibody in
a standard ECLTM (RPN 2106) reagent on HyperfilmTM enhanced
chemoluminescence (RPN 3103K; Amersham Bioscience and Den-
mark). Densitometric analysis of the band intensity was carried out
using Kodak one-dimensional imaging analysis software.
The following antibodies were used: anti-p38 MAPK and anti-
phospho-p38 MAPK (Thr180/Tyr182), anti-MAPKAP2 and anti-
phospho-MK2 (Thr334) mRab, anti-ERK1/2, and anti–ERK1/2 (Thr
202/Tyr 204), anti-phospho-MSK1 (Ser376), anti-MSK2, and anti-
phospho-MSK2 (Ser196), anti-NF-kB p65 and anti-phopho–NF-kB
p65 (Ser276), anti-CREB (no. 9197), and anti-phospho-CREB
(Ser133) and horseradish peroxidase anti-rabbit no. 7074 were from
Cell Signaling Technology, anti-MSK1 (H-19) from Santa Cruz
Biotechnology (Santa Cruz, CA). Horseradish peroxidase-labeled
swine anti-rabbit P0217, anti-goat P0449, anti-mouse P0447 were
from Dako Cytomation (Copenhagen, Denmark). Anti-phospho-
MSK2 (Ser196)/RSKB and anti-MSK-2/RSKB were from R&D
Systems.
LDH release membrane integrity assay
LDH released from cells with compromised membranes was assayed
using the CytoTox-OneTM homogeneous membrane integrity assay
(G7891, Promega, Denmark). Keratinocyte, 10,000 cells/well in
triplicates, in 96-well plates were stimulated as described above and
after 30 minutes stimulation with vehicle or IL-1b, 100ml of CytoTox-
One reagent was added to each well and LDH assay was allowed to
proceed for 10 minutes before addition of 50ml/well stop solution.
Flourescence was recorded at a wavelength of 590 nm using
Fluoroskan Ascent Fl (Labsystems, Serial: 374020271C, Denmark).
Maximum LDH release control was 2ml of lysis solution added to
positive control cells before addition of reagent. Percent cytotoxicity
was calculated as ratio 100 experimental/maximum LDH release.
Electrophoretic mobility shift assay
Electrophoretic mobility gel shift assays were performed as described
previously (Johansen et al., 2000). Keratinocytes were cultured until
80% confluence and then medium was changed to keratinocyte
basal medium for 24 hours. Then DMF, MHF, or FA was added for
1 hour before stimulation with IL-1b. In control cells only vehicle or
DMF, MHF, or FA was added. Cells were collected after 0, 30, and
60 minutes stimulation. Cells were washed with ice-cold PBS buffer
2 times and kept at 801C until further treatment. Nuclear proteins
were prepared as described previously (Johansen et al., 2005a, b).
Binding reactions consisted of 5 mg of nuclear protein, preincubated
for 10 minutes at room temperature in the incubation buffer (5 mM
MgCl2, 2.5 mM EDTA, 2.5 mM dithiothreitol, 250 mM NaCl, 50 mM
Tris–HCl, pH 7.5, 20% glycerol, 0.25 mg/ml poly(dI-dC)). The
oligonucleotides were labeled with 32P-ATP by T4 polynucleotide
kinase (Promega). Labeled oligonucleotides were purified on Nick
Spin column (G-50, 17-0855-02, Pharmacia, Sweden). Then, 1.5 ml
of 32P-labeled NF-kB probe was added to the binding reactions and
incubations were extended for additional 20 minutes.
Human IL-8 consensus NF-kB 50-CAAATCGTGGAATTTCCTC-30
and human IL-20 consensus NF-kB 50-GCG CTG TGG AGT CCC
AGA CAC G-30 or NF-kB1 50-GAG GAG GGG AAA CTC AGT AAG
T-30 was purchased from DNA Technology, AIS (Aarhus, Denmark).
The binding complexes were resolved on a 6% polyacrylamide gel
in 0.5 Tris-borate–EDTA buffer (22.5 mM Tris base, 4 mM boric acid,
and 1 mM EDTA).
Supershift reactions included anti-p65 antibody (sc-7151 X) and
anti-p50 (sc-7178 X) antibody from Santa Cruz Biotechnology (Santa
Cruz, CA). To the IL-1b-stimulated nuclear proteins in incubation
buffer, 2ml of anti-p65 antibody (or anti-p50 antibody) was added for
20 minutes before the addition of poly(dI-dC) and the radio-labeled
NF-kB probe.
Isolation of RNA and quantitative reverse transcriptase–PCR
RNA was purified with SV 96 total RNA isolation system (Promega,
Madison, WI). Briefly, 100ml of SV RNA lysis buffer was added
and lysates prepared by manually scraping the bottom of the wells.
The lysates were transferred to sterile Eppendorf tubes and kept
at 801C until RNA purification. On RNA purification the
samples were carefully thawed while on ice and transferred to
the wells of the SV 96-binding plates. Total RNA was purified
according to the protocol as described by the manufacturer.
Ultimately, RNA was dissolved in RNase/DNase-free water
and stored at 801C until further use. Quantitative reverse
transcriptase–PCR were performed as described previously by
Otkjaer et al. (2005) and Johansen et al. (2006). All primers and
probes were Taqman 20 assay-on demand (FAM-labeled MGB-
probes) gene expression assay mix. (assay ID: IL-20:
Hs00218888_ml, IL-8: Hs00174103_ml, 18 seconds rRNA:
Hs99999901_s1. (Applied Biosystems, Foster City, CA).
Statistics
Results were expressed as mean7SD. Statistical significance
(Po0.05) was assessed by Student’s t-test. To test for normal
distribution, a probability test was conducted.
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